Healthcare Sep 07, 2020 01:40 PM (GMT+8) · EqualOcean
Singleron Biologics, a Nanjing-based research startup, recently closed the Series A at USD 30 million. Lily Asia Ventures led the investment, joined by CDH Fund, Guoxin Fund, ARCH Venture Partners, Tencent Investment and existing investors, including Sherpa VC and China Growth Capital. The bankroll will help Singleron accelerate the research for single-celled sequencing, medical application development, and domestic commercialization for self-developed products. So far, the company has raised a total fund of over CNY 300 million. Founded in 2018, the startup has provided technology and services for over 160 prestigious hospitals, pharmaceutical groups and research institutions. The global market potential for single-celled sequencing has reached USD 13 billion, with versatile functions for single-celled sequencing.